文献速递结核与非结核分枝杆菌

新生儿接种卡介苗后的全身播散是否为抵御结核分枝杆菌感染所必需

Is Systemic Dissemination of BCG Following Neonatal Vaccination Required for Protection Against Mycobacterium tuberculosis?
PubMed 文献 · J Infect Dis · 2025-01-01

本文提出假说:新生儿皮内接种卡介苗可导致低度卡介苗菌血症,这种全身播散有助于提高对结核分枝杆菌感染的保护力;该假说基于动物与人体研究证据,尚待验证,但有望为全球结核防控提供可操作的见解。

要点

  • 新生儿皮内接种卡介苗可能引起低度卡介苗菌血症。
  • 卡介苗全身播散可能增强对结核分枝杆菌感染的保护。
  • 该假说可检验,或为结核防控提供可操作思路。

核心结论

  • 作者假说:新生儿皮内接种卡介苗导致的低度菌血症及全身播散,可能提高对结核分枝杆菌感染的保护力。

研究设计与样本

  • 原文为假说性文章,基于动物与人体研究的支持性观察提出可检验假说。

主要发现

  • 临床前研究显示,成人静脉接种卡介苗可提高对结核的保护。
  • 作者据此推测新生儿皮内接种卡介苗或可引发低度卡介苗菌血症并促进全身播散。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文为假说,尚待验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb) and is a leading cause of death. BCG is the only licensed TB vaccine. Preclinical studies have shown that in adults, intravenous administration of BCG improves protection against TB. We hypothesize that intradermal administration of BCG to the human newborn leads to low-grade BCG bacteremia and that this systemic dissemination improves protection against Mtb infection. This hypothesis is based on supporting observations including animal and human studies. It is a testable hypothesis and offers to deliver immediately actionable insight to advance the global efforts against TB.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kollmann TR, Amenyogbe N, Schaltz-Buchholzer F, et al. Is Systemic Dissemination of BCG Following Neonatal Vaccination Required for Protection Against Mycobacterium tuberculosis? J Infect Dis. 2025. PMID: 39913242. doi:10.1093/infdis/jiaf051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。